Amikacin Inj Rx
Generic Name and Formulations:
Amikacin sulfate 100mg/2mL, 500mg/2mL, 1g/4mL; soln for IM inj or IV infusion after dilution; contains sulfites.
Various generic manufacturers
Indications for Amikacin Inj:
Short-term treatment of serious susceptible infections, including septicemia, respiratory tract, bones and joints, CNS (eg, meningitis), skin and skin structure, intra-abdominal (eg, peritonitis), burns and postoperative infections, complicated and recurrent UTIs or uncomplicated UTIs not susceptible to other antibiotics.
Give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Heavier wt. patients: max 1.5g/day. Usual duration: 7–10 days. Uncomplicated UTIs: 250mg twice daily. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Infants: give by IM inj; or IV infusion over 1–2 hours. Newborns: loading dose: 10mg/kg; then follow with 7.5mg/kg every 12 hours. All other children and older infants: give by IM inj; or IV infusion over 30–60 mins. 15mg/kg per day in 2–3 divided doses (7.5mg/kg every 12 hours or 5mg/kg every 8 hours); max 15mg/kg/day. Usual duration: 7–10 days. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >35micrograms/mL and trough levels >10micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Monitor BUN, CrCl, serum creatinine levels before, frequently during, and after therapy. Perform audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism, or infant botulism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Avoid concomitant furosemide, ethacrynic acid. Diuretics may increase toxicity. Increased risk of neurotoxicity and/or nephrotoxicity with concurrent or sequential polymyxin B, colistin, amphotericin B, other nephrotoxic or neurotoxic drugs; avoid. May potentiate neuromuscular blockade, respiratory paralysis with anesthetics, neuromuscular blockers. May be antagonized by concomitant penicillins, cephalosporins.
Nephrotoxicity (eg, azotemia, oliguria), ototoxicity, neurotoxicity, neuromuscular blockade (eg, muscular paralysis, apnea); rare: rash, drug fever, headache, tremor, GI upset, paresthesia, eosinophilia, arthralgia, anemia, hypotension, hypomagnesium.
Formerly known under the brand name Amikin.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|